#GLP1 #Pharma #Strategy #MarketAccess #PharmaGambit To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] To view or add a comment, sign in Imagine telling a pharmacist in 2015: A diabetes drug will soon be used for weight loss, heart protection, kidney disease, fatty liver disease, and even sleep apnea. Most people would have laughed

Shawna Stash obtained a prescription for injectable semaglutide/cyanocobalamin compounded by Empower Pharmacy
What to Do After a Positive Pregnancy Test
GLP-1 lawsuit claims center on allegations that manufacturers of medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 receptor agonist drugs failed to adequately warn patients and physicians about serious health risks associated with these medications
Back at GSK he remembers waiting for phase 3 results, with champagne on ice, only to be disappointed by last minute indications of liver toxicity